Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547884 · ClinicalTrials.gov registry record
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 4,268
- Enrollment target
NCT01547884: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01547884 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,268 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547884 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 4,268 participants
- Enrollment target
Study Summary
Background: \- Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches. If untreated, it can also cause elephantiasis, a condition that leads to swelling of the arms, legs, breasts, and scrotum. Treatment can eliminate the worms from the blood and reduce the risk of developing elephantiasis. Researchers want to study people with latent tuberculosis (TB) who may or may not be infected with filariasis. This study will look at the way that people with latent TB fight infection with these worms. Objectives: \- To study how the immune systems of people with latent TB react to filarial infection. Eligibility: \- Individuals between 18 and 65 years of age who have latent TB and may or may not have filarial infection. Design: * Participants will be screened with a physical exam and medical history. They will provide a blood and stool sample to test for infection. * Participants who do not have lymphatic filariasis but have another kind of intestinal worm will be treated for the parasite. This will be their last study visit. * Participants who have latent TB and lymphatic filariasis will be treated with the standard treatment for the disease. They will come back for a second visit 6 months later, and will provide another blood sample.
Primary Outcome
pending
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,268 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2020-08-07 |
What the finished NCT01547884 record still lists
NCT01547884 is an observational study that tracks outcomes without assigning an intervention. Its 4,268 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01547884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01547884 about?
NCT01547884 is a clinical study titled "Effect of Filarial Infection on Immune Responses in Latent Tuberculosis". Background: \- Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches. If untreated, it can also cause elephantiasis, a condition that leads to swelling of the arms, legs, breasts, and scrotum. Treatment c...
What is the current status of trial NCT01547884?
This trial is currently completed. The enrollment target is 4,268 participants. The study started on 2013-01-01. Estimated completion is 2020-08-07.
Who is sponsoring clinical trial NCT01547884?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI